IP Library Granted Patent US 8,303,962
Granted Patent B2
US 8,303,962 · App. 12/683,188 · Granted Nov 6, 2012

Antibacterial and antifungal peptides

Assignee: C3 Jian, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,303,962
App. No.
12/683,188
Granted
Nov 6, 2012
Kind
B2
Abstract

This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.

Claims (9)

1. An isolated antimicrobial peptide having antimicrobial activity against at least one kind of bacteria, fungus, or yeast, said antimicrobial peptide ranging in length up to 25 amino acids wherein the amino acid sequence of said peptide comprises the sequence SLQSQLGPCLHDQRH (PF-448, SEQ ID NO:19), and wherein said peptide has antimicrobial activity against Streptococcus pneumoniae .

2. The antimicrobial peptide of claim 1 , wherein the amino acid sequence of said peptide consists of the amino acid sequence SLQSQLGPCLHDQRH (PF-448, SEQ ID NO:19).

3. The antimicrobial peptide of claim 1 , wherein said peptide comprises all “L” amino acids.

4. The antimicrobial peptide of claim 1 , wherein said peptide comprises all “D” amino acids.

5. The antimicrobial peptide of claim 1 , wherein said peptide is a β peptide.

6. The antimicrobial peptide of claim 1 , wherein said peptide comprises one or more protecting groups.

7. The antimicrobial peptide of claim 1 , wherein said peptide is in a pharmaceutically acceptable carrier.

8. The antimicrobial peptide according to claim 7 , wherein said carrier is suitable for administration via a route selected from the group consisting of topical administration, aerosol administration, administration via inhalation, oral administration, systemic IV application, ocular administration, and rectal administration.

9. A method of killing and/or inhibiting the growth and/or proliferation of a microorganism, said method comprising contacting said microorganism with a peptide of claim 1 .

Assignments (8)
SECURITY INTEREST Recorded May 20, 2026
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 074715/0208 →
SECURITY INTEREST Recorded Aug 14, 2025
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 072025/0567 →
SECURITY INTEREST Recorded Mar 17, 2025
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 070532/0979 →
SECURITY INTEREST Recorded Mar 5, 2024
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 066657/0409 →
SECURITY INTEREST Recorded Jul 14, 2023
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 064262/0958 →
SECURITY INTEREST Recorded Feb 17, 2023
From: ARMATA PHARMACEUTICALS, INC.; C3J THERAPEUTICS, INC.; C3 JIAN, LLC
To: INNOVIVA STRATEGIC OPPORTUNITIES LLC
Reel/Frame 062733/0983 →
CHANGE OF NAME Recorded Jul 21, 2017
From: C3 JIAN, INC.
To: C3 JIAN, LLC
Reel/Frame 043302/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2010
From: ECKERT, RANDAL H.; KAPLAN, CHRIS; HE, JIAN; YARBROUGH, DANIEL K.; ANDERSON, MAXWELL; SIM, JEE-HYUN
To: C3 JIAN, INC.
Reel/Frame 024452/0990 →
Continuity (5)
Provisional Application 61142830 · Jan 6, 2009
Provisional Application 61151445 · Feb 10, 2009
Provisional Application 61243905 · Sep 18, 2009
Provisional Application 61243930 · Sep 18, 2009
Related Publication 20100184681A1 · Jul 22, 2010